Deutsche Bank AG Has $1.12 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

Deutsche Bank AG lifted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 53.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 38,978 shares of the company's stock after purchasing an additional 13,589 shares during the period. Deutsche Bank AG owned 0.05% of CG Oncology worth $1,118,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in CGON. Barclays PLC raised its position in CG Oncology by 331.1% in the 3rd quarter. Barclays PLC now owns 90,520 shares of the company's stock worth $3,416,000 after purchasing an additional 69,523 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of CG Oncology during the 4th quarter worth about $411,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of CG Oncology during the 4th quarter worth about $68,000. Rhumbline Advisers raised its holdings in shares of CG Oncology by 2.2% in the 4th quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock valued at $1,979,000 after purchasing an additional 1,458 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in CG Oncology by 16.7% in the 4th quarter. New York State Common Retirement Fund now owns 13,996 shares of the company's stock valued at $401,000 after acquiring an additional 2,000 shares during the period. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Stock Performance

Shares of CGON traded down $0.50 during midday trading on Friday, hitting $25.74. The company had a trading volume of 67,245 shares, compared to its average volume of 826,259. The company's 50-day simple moving average is $23.09 and its 200-day simple moving average is $27.43. The firm has a market capitalization of $1.96 billion, a P/E ratio of -16.91 and a beta of 1.08. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09). The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.53 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. Equities analysts predict that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Activity at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.40% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Morgan Stanley cut their target price on shares of CG Oncology from $55.00 to $52.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Cantor Fitzgerald reiterated an "overweight" rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, April 28th. JPMorgan Chase & Co. initiated coverage on shares of CG Oncology in a research note on Friday, May 2nd. They issued an "overweight" rating and a $41.00 target price on the stock. Scotiabank assumed coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 target price on the stock. Finally, Royal Bank of Canada increased their price target on shares of CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a report on Tuesday, April 29th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $58.22.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.